The findings offer, for the first time, a set of standard treatment guidelines for recurrence prevention in this group of patients. Previous studies of chemotherapy plus targeted therapy in women with HER2-positive breast cancer that hadn't spread to nearby lymph nodes included few patients whose tumors were comparatively small (less than 3 cm in diameter). [Breast cancers are deemed HER2-positive if their cells have surplus human epidermal growth factor receptors on their surface, making them extra-sensitive to signals to grow and divide.]
"Smaller, HER2-positive, node-negative [no sign of spread to the lymph nodes] breast cancers are thought to have a high-enough chance of recurring that many doctors have offered patients a combination of chemotherapy and Herceptin [a targeted therapy] to reduce that risk," says the study's senior author, Eric Winer, MD, chief of the division of Women's Cancers in the Susan F. Smith Center for Women's Cancers at Dana-Farber. "But, as this approach hadn't been tested in many women with smaller tumors, we lacked a standard approach to preventing cancer recurrence in these women."
Because of the sometimes difficult side effects of the conventional drug regimens against recurrence - which can include the chemotherapy drugs adriamycin, taxotere, and carboplatin, plus Herceptin - investigators opted for a less harsh combination of the chemotherapy agent paclitaxel and Herceptin. The study enrolled 406 patients with HER2-positive, node-negative breast tumors smaller than 3 cm. They were treated with the drug combination for 12 weeks, followed by nine months of Herceptin alone.
After a median follow-up of 3.6 years, only two or three of the study participants experienced a recurrence of their cancer ÂŽ- accounting for less than 2 percent of the entire group - of developed other health problems.
"The findings suggest that for many women with this type of breast cancer, this regimen should be considered one of the standard strategies for recurrence prevention," Winer remarks.
The lead author of the study is Sara Tolaney, MD, of Dana-Farber. Co-authors include William Barry, PhD, Beth Overmoyer, MD, Ann Partridge, MD, Hao Guo, Ian Krop, MD, PhD, and Harold Burstein, MD, PhD, of Dana-Farber; Chau Dang MD, and Clifford Hudis, MD, of Memorial Sloan-Kettering Cancer Center; Denise Yardley, MD, of the Sarah Cannon Cancer Center, Nashville, Tenn.; Beverly Moy, MD, of Massachusetts General Hospital; P. Kelly Marcom, MD, of Duke University; Kathy Albain, MD, of Loyola University; Hope Rugo, MD, of the University of California San Francisco; Matthew Ellis, MD, PhD, of Washington University; Iuliana Shapira, MD, of Hofstra North Shore Long Island Jewish School of Medicine; Antonio Wolff, MD, of Johns Hopkins Kimmel Cancer Center; and Lisa A. Carey, MD, of the University of North Carolina.
Dana-Farber Cancer Institute is a principal teaching affiliate of the Harvard Medical School and is among the leading cancer research and care centers in the United States. It is a founding member of the Dana-Farber/Harvard Cancer Center, designated a comprehensive cancer center by the National Cancer Institute. It provides adult cancer care with Brigham and Women's Hospital as Dana-Farber/Brigham and Women's Cancer Center and it provides pediatric care with Boston Children's Hospital as Dana-Farber/Boston Children's Cancer and Blood Disorders Center. Dana-Farber is the top ranked cancer center in New England and fifth nationally, according to U.S. News & World Report, and one of the largest recipients among independent hospitals of National Cancer Institute and National Institutes of Health grant funding. Follow Dana-Farber on Facebook and Twitter.